Literature DB >> 10613922

HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line.

K Kunath1, P Kopecková, T Minko, J Kopecek.   

Abstract

The effect of an N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-Adriamycin-OV-TLl6 antibody conjugate [P(GFLG)-ADR-Ab] on OVCAR-3 human ovarian carcinoma cells was studied. A nontargeted HPMA copolymer-ADR conjugate (P(GFLG)-ADR) and free ADR were the controls. The IC(50) doses were 0.65, 3.0, and 65 microM for free ADR, targeted P(GFLG)-ADR-Ab conjugate, and nontargeted P(GFLG)-ADR conjugate, respectively. These differences reflect the different mechanisms of cell entry of the compounds evaluated. Free ADR and HPMA copolymer-ADR conjugates had different impacts on the expression of MDR1, MRP, c-fos, c-jun, and bcl-2 genes which encode the P-glycoprotein (MDR1) and the multidrug resistance-associated protein (MRP) efflux pumps, and play an important role in cell death signaling pathways (c-fos, c-jun, and bcl-2). Whereas high doses of free ADR induced MDR1 gene expression, HPMA copolymer-bound ADR appeared to be without effect. On the contrary, expression of the MRP gene was not influenced by free ADR, whereas HPMA copolymer-ADR conjugates seemed to suppress the gene expression in a concentration-dependent manner. There were differences in the expression of c-fos, c-jun, and bcl-2 genes after the incubation of OVCAR-3 cells with free and HPMA copolymer-bound ADR indicating differences in activation of cell death signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10613922     DOI: 10.1016/s0939-6411(99)00033-8

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  4 in total

1.  Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells.

Authors:  T Minko; P Kopecková; J Kopecek
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

2.  Preparation, drug release, and cell growth inhibition of a gelatin: doxorubicin conjugate.

Authors:  Darren C Wu; Christopher R Cammarata; Hyun Joo Park; Brian T Rhodes; Clyde M Ofner
Journal:  Pharm Res       Date:  2013-05-18       Impact factor: 4.200

Review 3.  Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery.

Authors:  Julia Y Ljubimova; Manabu Fujita; Alexander V Ljubimov; Vladimir P Torchilin; Keith L Black; Eggehard Holler
Journal:  Nanomedicine (Lond)       Date:  2008-04       Impact factor: 5.307

Review 4.  Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review).

Authors:  Yan-Jun Zhong; Li-Hua Shao; Yan Li
Journal:  Int J Oncol       Date:  2012-12-28       Impact factor: 5.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.